Anya Biopharm, Inc.
TTPEX:777631.95
TWD
-0.10
(-0.31%)
ISIN
TW0007776007
Return %
Stock
S&P 500
1Y
-36.35
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Taipei Taiwan
- IPO Date
- Oct 25, 2024
- Website
- anyabiopharm.com
- Similar Companies
- Business
- Anya Biopharm, Inc. is a Taiwan-based medical technology and biotechnology company specializing in the research, development, manufacturing, and commercialization of advanced wound care dressings, specialized medical devices, and surgical consumables. Founded in 2008 and headquartered in New Taipei City, Taiwan, the company operates across clinical healthcare, surgical care, and consumer wound management segments, supplying medical centers, regional hospitals, specialized clinics, and retail pharmacy networks. The company's core product and service offerings are structured across several primary categories: advanced wound management solutions, which include hydrogel dressings, antibacterial silver dressings, post-operative incisional dressings, liquid bandage formulations, transparent waterproof film dressings, and intravenous catheter securement devices marketed primarily under its proprietary HeraDerm brand; scar care and management products, comprising medical-grade silicone scar sheets, scar reduction gels, and post-procedural skin repair formulations; surgical and specialty medical devices, featuring bio-absorbable surgical anti-adhesion barriers, patient-controlled analgesia infusion pumps, disposable elastomeric infusion systems, endoscopic surgical accessories, and electrosurgical instruments; and aesthetic dermatology and post-operative skin care products, consisting of medical skin barrier repair formulations, post-laser soothing masks, and topical dermatological treatments. In addition to in-house research, product development, and certified cleanroom manufacturing, the company provides distribution and agency services for international surgical instruments, orthopedic consumables, and specialized clinical care equipment. Anya Biopharm conducts business domestically across Taiwan and internationally across key Asia-Pacific markets, including Mainland China, Vietnam, Thailand, Malaysia, Singapore, and Indonesia, while actively pursuing medical device registrations in additional overseas jurisdictions. In recent developments, Anya Biopharm completed its listing on the Emerging Stock Board of the Taipei Exchange (TPEx: 7776), representing a significant step in its corporate expansion and capital market access. The company has accelerated its international commercialization initiatives by establishing distribution alliances and securing medical device regulatory approvals for its HeraDerm advanced dressing series across Southeast Asian markets. Furthermore, Anya Biopharm has expanded its domestic manufacturing capacity with upgraded automated production facilities to scale the rollout of its next-generation biomaterial dressings and anti-adhesion products, while broadening its commercial distribution through expanded partnerships with hospital networks and retail healthcare chains.